Athira Pharma Inc
Change company Symbol lookup
Select an option...
ATHA Athira Pharma Inc
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
NEE Nextera Energy Inc
PSB-Y PS Business Parks Inc
ADBE Adobe Inc
APWL Advanced Powerline Technologies Inc

Health Care : Pharmaceuticals |
Company profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform, ATH platform and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. Its lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). The Company also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019 / ATH-1020 compounds, which are being advanced to address neuropsychiatric indications.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Archer Daniels takes major stake in pet treat and supplement manufacturers

2:51 pm ET September 8, 2021 (MarketWatch)

Archer Daniels Midland Co. (ADM) said Wednesday that it has taken a 75% equity stake in private-label pet treat and supplement manufacturers PetDine, Pedigree Ovens, The Pound Bakery and NutraDine. The transaction values the four enterprises, also called P4 Companies, at $600 million. They have 300 employees, 650 customers across 15 countries, and make products like treats, liquids and powders for pets. Archer Daniels will also acquire production facilities in Illinois and Colorado. Vince Macciocchi, president of Archer Daniels' Nutrition business, said in a statement that the deal is part of the pursuit of the growing pet nutrition business, with global annual sales of pet food projected to grow to $140 billion by 2026 and pet treats growing at an even faster rate. Archer Daniels could purchase the remaining 25% in the coming years. Archer Daniels shares have gained 18.8% for the year to date while the S&P 500 index has gained 20% for the period.

-Tonya Garcia


(END) Dow Jones Newswires

September 08, 2021 14:51 ET (18:51 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.